Hemostemix Inc Cash Flow Conversion Efficiency

Latest as of September 2025: 0.839x

Hemostemix Inc cash flow conversion efficiency. Based on the latest financial reports, Hemostemix Inc (HEM) has a cash flow conversion efficiency ratio of 0.839x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-2.91 Million ≈ $-2.10 Million USD) by net assets (CA$-3.46 Million ≈ $-2.50 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Hemostemix Inc (2013–2024)

Cash flow conversion efficiency of Hemostemix Inc from 2013 to 2024. This chart illustrates how Hemostemix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Hemostemix Inc (HEM) share price today for real-time trading data and today's change.

Hemostemix Inc Cash Flow Conversion Ratio Explained

Hemostemix Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Hemostemix Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Hemostemix Inc ranked by their cash flow conversion efficiency. Also see HEM company net worth for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
ECP Emerging Growth Ltd AU:ECP	-0.023x
Ensysce Biosciences Inc NASDAQ:ENSC	1.767x
Aterian Inc NASDAQ:ATER	-0.069x
Tempest Therapeutics Inc NASDAQ:TPST	2.550x
Shanghai Broadband Technology Co Ltd SHG:600608	0.540x
Warisan TC Holdings Bhd KLSE:5016	0.095x
AVRO INDIA LIMITED NSE:AVROIND	-0.035x
Aumake Ltd AU:AUK	0.022x

Annual Cash Flow Conversion Efficiency for Hemostemix Inc (2013–2024)

The table below shows the annual cash flow conversion efficiency of Hemostemix Inc from 2013 to 2024. Review Hemostemix Inc free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CA$-7.20 Million ≈ $-5.21 Million	CA$-1.90 Million ≈ $-1.38 Million	0.264x	+29.94%
2023-12-31	CA$-7.37 Million ≈ $-5.33 Million	CA$-1.50 Million ≈ $-1.08 Million	0.203x	-77.46%
2022-12-31	CA$-6.77 Million ≈ $-4.90 Million	CA$-6.10 Million ≈ $-4.41 Million	0.901x	+36.96%
2021-12-31	CA$-5.28 Million ≈ $-3.82 Million	CA$-3.48 Million ≈ $-2.52 Million	0.658x	-87.90%
2020-12-31	CA$-1.10 Million ≈ $-794.78K	CA$-5.98 Million ≈ $-4.32 Million	5.438x	+546.31%
2019-12-31	CA$-4.05 Million ≈ $-2.93 Million	CA$-3.40 Million ≈ $-2.46 Million	0.841x	+115.26%
2018-12-31	CA$487.80K ≈ $352.87K	CA$-2.69 Million ≈ $-1.95 Million	-5.513x	-730.03%
2017-12-31	CA$4.84 Million ≈ $3.50 Million	CA$-3.21 Million ≈ $-2.32 Million	-0.664x	-185.48%
2016-12-31	CA$-3.46 Million ≈ $-2.50 Million	CA$-2.69 Million ≈ $-1.95 Million	0.777x	+103.82%
2015-12-31	CA$174.08K ≈ $125.93K	CA$-3.55 Million ≈ $-2.56 Million	-20.365x	-2102.29%
2014-12-31	CA$3.39 Million ≈ $2.45 Million	CA$-3.13 Million ≈ $-2.27 Million	-0.925x	+52.07%
2013-12-31	CA$573.87K ≈ $415.13K	CA$-1.11 Million ≈ $-800.95K	-1.929x	--

About Hemostemix Inc

V:HEM Canada Biotechnology

Market Cap

$8.18 Million

CA$11.31 Million CAD

Market Cap Rank

#27442 Global

#1143 in Canada

Share Price

CA$0.06

Change (1 day)

+0.00%

52-Week Range

CA$0.05 - CA$0.11

All Time High

CA$13.40